Algernon Pharmaceuticals (AGN Pharma) has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance its DMT stroke programme.
With psychedelics and psychedelic-assisted psychotherapy showing promise as potential treatments for mental health conditions, skilled facilitators who can provide therapy for patients and in clinical trials...
The Psychedelics as Medicine Report has revealed the industry is currently worth US$650 million (~£542 million), and is expected to exceed US$3 billion by 2026.
Psychedelics venture studio Nucleus has raised USD$135,000 from investors through its Wefunder campaign.
Former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, has been appointed to the role of Executive Special Advisor by Clearmind Medicine.
BetterLife Pharma has secured investment from Negev Capital and further European investors that will go towards working capital purposes and the advancement of pre-clinical and clinical...
Awakn Life Sciences has announced that it has signed a five-year lease to open Awakn Clinics Trondheim.
Psyrise, a mental health marketing company located in South Florida, has released a first-of-its-kind marketing platform for health practitioners in the field of psychedelic therapies.
Irwin Naturals is branching into the psychedelics space with the aim of establishing the world’s largest chain of psychedelic mental health clinics.
Sintalica Bioscience has received, through the University of Messina, authorisations from the Italian Ministry of Health pertaining to its drug development programme.